PPARG and lung cancer: Similarly, although the anti-diabetic drug TZDs are in clinical trials for lung cancer treatment, molecular function of the TZD-activated PPARγ has not been clearly defined yet as an anti-tumorigenic factor in lung cancer, or even argued as a tumor-promoting factor in other types of cancers, i.e. breast cancer and prostate cancer [28–30].